Performance enhancement of organic photovoltaic cells through nanostructuring and molecular doping

Die vorliegende Arbeit beschäftigt sich mit der Leistungssteigerung organischer Solarzellen durch Änderung der Geometrie an der Donor-Akzeptor Grenzfläche und dem Einstellen der elektronischen Eigenschaften von Grenzflächen durch molekulares p-Dotieren. Kristalline und gleichmäßige Nanosäulen aus dem organischen Halbleiter Pentazen wurden durch glancing angle deposition (GLAD) hergestellt, die einen ineinandergreifenden Heteroübergang zu Methanofulleren [6,6]-Phenyl-C61-Butansäure Methylester (PCBM) als Akzeptor ermöglichten. Die Kurzschlussspannung der nanosäulenbasierten Solarzellen war signifikant erhöht im Vergleich zu planaren Heteroübergängen zwischen denselben Materialien. Die Leistungssteigerung der Solarzellen konnte maßgebend der vergrößerten Grenzfläche zugewiesen werden, wegen des verringerten Einflusses der kurzen Exciton Diffusionslänge. Molekulares p-Dotieren mit Tetrafluorotetracyanoquinodimethan (F4TCNQ) als Dotand in polyfuranbasierten Solarzellen wurde für verschiede Dotierkonzentrationen untersucht. Ultraviolettphotoelektronenspektroskopie wurde verwendet, um die Veränderungen der Energieniveaus mit zunehmender Dotierkonzentration zu analysieren, welche zu einer Vergrößerung der 0,2 V Kurzschlussspannung auf bis zu 0,4 V führte. Nach Kombination dieser Beobachtung mit Ergebnissen an dotierten Polymerfilmen, insbesondere bezüglich deren Morphologie und Absorptionsverhalten, wurde vorgeschlagen, dass ein resultierender Dipol an der Donor-Akzeptorgrenzfläche präsent ist. Zusammenfassend zeigt die vorliegende Arbeit das Potential sowohl der GLAD Technik als auch des molekularen, elektrischen Dotierens für die Leistungsverbesserung organischer Solarzellen.The present work mainly focuses on improving the performance of OPVCs by tailoring the donor-acceptor interface geometry and by tuning the electrical properties of interfaces with p-type molecular doping. Crystalline and uniform nanocolumns of pentacene (PEN) and diindenoperylene (DIP) were fabricated by glancing angle deposition (GLAD), forming an interdigitated donor/acceptor heterojunction with [6,6]-phenyl-C61-butyric acid methyl ester (PCBM) and/or fullerene as the electron acceptor. The short circuit current of nanocolumn-based OPVCs increased significantly compared to planar heterojunction OPVCs made from the same materials. The performance improvement of OPVCs had been verified to be contributed decisively by the donor-acceptor interface area enlargement because of reduced impact of short exciton diffusion length in organic materials. P-type molecular doping as applied in polyfuran (PF) based OPVCs was investigated by using tetrafluorotetracyanoquinodimethane (F4-TCNQ) as the dopant for various doping ratios. Ultraviolet photoelectron spectroscopy (UPS) was applied to analyze the energy level shift with increasing doping ratio leading to the enlargement of the open circuit voltage in OPVCs, from 0.2 V to close to 0.4 V. Combining this observation with the results of doped polymer films, their morphology and absorption behavior, a net dipole pointing towards the donor material at the donor-acceptor interface of OPVCs is proposed. Overall, this work demonstrates the potential of both the GLAD technique and molecular electrical doping for improving the performance of OPVCs

A novel pyruvate kinase and its application in lactic acid production under oxygen deprivation in Corynebacterium glutamicum

BACKGROUND: Pyruvate kinase (Pyk) catalyzes the generation of pyruvate and ATP in glycolysis and functions as a key switch in the regulation of carbon flux distribution. Both the substrates and products of Pyk are involved in the tricarboxylic acid cycle, anaplerosis and energy anabolism, which places Pyk at a primary metabolic intersection. Pyks are highly conserved in most bacteria and lower eukaryotes. Corynebacterium glutamicum is an industrial workhorse for the production of various amino acids and organic acids. Although C. glutamicum was assumed to possess only one Pyk (pyk1, NCgl2008), NCgl2809 was annotated as a pyruvate kinase with an unknown role. RESULTS: Here, we identified that NCgl2809 was a novel pyruvate kinase (pyk2) in C. glutamicum. Complementation of the WTΔpyk1Δpyk2 strain with the pyk2 gene restored its growth on d-ribose, which demonstrated that Pyk2 could substitute for Pyk1 in vivo. Pyk2 was co-dependent on Mn(2+) and K(+) and had a higher affinity for ADP than phosphoenolpyruvate (PEP). The catalytic activity of Pyk2 was allosterically regulated by fructose 1,6-bisphosphate (FBP) activation and ATP inhibition. Furthermore, pyk2 and ldhA, which encodes l-lactate dehydrogenase, were co-transcribed as a bicistronic mRNA under aerobic conditions and pyk2 deficiency had a slight effect on the intracellular activity of Pyk. However, the mRNA level of pyk2 in the wild-type strain under oxygen deprivation was 14.24-fold higher than that under aerobic conditions. Under oxygen deprivation, pyk1 or pyk2 deficiency decreased the generation of lactic acid, and the overexpression of either pyk1 or pyk2 increased the production of lactic acid as the activity of Pyk increased. Fed-batch fermentation of the pyk2-overexpressing WTΔpyk1 strain produced 60.27 ± 1.40 g/L of lactic acid, which was a 47% increase compared to the parent strain under oxygen deprivation. CONCLUSIONS: Pyk2 functioned as a pyruvate kinase and contributed to the increased level of Pyk activity under oxygen deprivation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12896-016-0313-6) contains supplementary material, which is available to authorized users

Efficacy and safety of serplulimab in solid tumors: a meta-analysis

ObjectiveThe goal of this study was to investigate the effectiveness and safety of serplulimab in advanced solid tumors through a meta-analysis approach.MethodsAn electronic search was conducted across the Embase, Web of Science, PubMed, and Cochrane Library databases, covering the period from each database’s inception through 6 May 2025. Meta-analysis and related analyses, including subgroup, sensitivity, and publication bias assessments, were performed using Stata 16.0. The Cochrane Risk of Bias Assessment Tool (version 5.1.0) was utilized to measure the quality of randomized controlled trials (RCTs). For single-arm studies, quality was evaluated using the Methodological Index for Non-Randomized Studies (MINORS).ResultsTen studies, including three RCTs and seven single-arm studies, were analyzed, involving 2,020 patients. In the analysis of RCTs, serplulimab significantly elevated overall survival (OS) [HR = 0.68, 95% CI: 0.59–0.79, P < 0.01], disease control rate (DCR) [RR = 1.04, 95% CI: 1.01–1.08, P < 0.05], progression-free survival (PFS) [HR = 0.53, 95% CI: 0.47–0.61, P < 0.01], and objective response rate (ORR) [RR = 1.30, 95% CI: 1.09–1.56, P < 0.01]. The analysis of single-arm studies revealed that the ORR for serplulimab in solid tumors was [ES = 45%, 95% CI: 31%–59%, P < 0.01], and the DCR was [ES = 71%, 95% CI: 63%–80%, P < 0.01]. Among the ten studies, the most common adverse events included reductions in platelet count (0.32, 95% CI: 0.20–0.43), white blood cell count (0.30, 95% CI: 0.17–0.44), anemia (0.29, 95% CI: 0.09–0.48), and proteinuria (0.28, 95% CI: 0.17–0.38).ConclusionBased on current research, serplulimab appears to be effective for solid tumors. However, given the limitations of the studies, for example, possible selection bias in single-arm studies, further multicenter, high-quality, large-sample RCTs are necessary to validate this conclusion

Causality adversarial attack generation algorithm for intelligent unmanned communication system

A causality adversarial attack generation algorithm was proposed in response to the causality issue of gradient-based adversarial attack generation algorithms in practical communication system.The sequential input-output features and temporal memory capability of long short-term memory networks were utilized to extract the temporal correlation of communication signals while satisfying practical causality constraints, and enhance the adversarial attack performance against unmanned communication systems.Simulation results demonstrate that the proposed algorithm outperforms existing causality adversarial attack algorithms, such as universal adversarial perturbation, under identical conditions

Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study

BackgroundAumolertinib demonstrated superior progression-free survival (PFS) and a well-tolerated toxicity profile compared to gefitinib in front-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in the AENEAS trial. However, patient-reported outcomes (PROs) of aumolertinib have not been published.MethodsIn this real-world study, the efficacy was evaluated by Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. PROs were evaluated using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (QLQ-C30) and the EORTC Quality of Life lung cancer-specific module (QLQ-LC13) in advanced NSCLC patients receiving aumolertinib as initial therapy. Pre-specified key symptoms were cough, hemoptysis, dyspnea, sore mouth or tongue, dysphagia, hair loss, tingling in hands or feet, chest pain, arm or shoulder pain, and pain at other sites.ResultsA total of 33 patients were included, 23 of whom had efficacy information up to January 2024. The median follow-up time was 264 days (interval: 36–491 days). The objective response rate and disease control rate were 65.2% and 91.3%, respectively. The EORTC QLQ-LC30 general health status scale showed that functional scales increased and symptom scales decreased during aumolertinib treatment. Symptom scales assessed by the EORTC QLQ-LC13 showed that improvements in cough, sore mouth or tongue, tingling in hands or feet, chest pain, arm or shoulder pain, and other pain sites were both clinically and statistically significant after 6 months of aumolertinib treatment (p < 0.05).ConclusionIn this real-world study, aumolertinib showed comparable disease control and objective response rates as reported in the AENEAS trial for advanced NSCLC patients with EGFR-sensitizing mutations. Aumolertinib treatment improved PROs, further supporting it in first-line clinical practice

CYP6AE gene cluster knockout in <i>Helicoverpa armigera</i> reveals role in detoxification of phytochemicals and insecticides

Cotton bollworm is an important agricultural pest with widespread resistance to insecticides. Here Wang et al. identifies CYP6AEs from cotton bollworm involved in detoxifying plant toxins and chemical insecticides through the CRISPR-Cas9-based reverse genetics approach in conjunction with in vitro metabolism

A COMPARATIVE STUDY OF FEEDFORWARD TUNING METHODS FOR WAFER SCANNING SYSTEMS

ABSTRACT Th

ZKPoG: Accelerating WitGen-Incorporated End-to-End Zero-Knowledge Proof on GPU

Zero-Knowledge Proof (ZKP) is a cornerstone technology in privacy-preserving computing, addressing critical challenges in domains such as finance and healthcare by ensuring data confidentiality during computation. However, the high computational overhead of ZKP, particularly in proof generation and verification, limits its scalability and usability in real-world applications. Existing efforts to accelerate ZKP primarily focus on specific components, such as polynomial commitment schemes or elliptic curve operations, but fail to deliver an integrated, flexible, and efficient end-to-end solution that includes witness generation. In this work, we present ZKPoG, a GPU-based ZKP acceleration platform that achieves full end-to-end optimization. ZKPoG addresses three key challenges: (1) designing a witness-generation-incorporated flow for Plonkish circuits, enabling seamless integration of frontend and backend with GPU acceleration; (2) optimizing memory usage to accommodate large-scale circuits on affordable GPUs with limited memory; and (3) introducing an automated compiler for custom gates, simplifying adaptation to diverse applications. Experimental results on an NVIDIA RTX 4090 GPU show on average $22.8\times$ end-to-end acceleration compared to state-of-the-art CPU implementations and on average $12.7\times$ speedup over existing GPU-based approaches